Inventor
TUCKER HOWARD
GB33 patents
⚠️ This page may combine multiple inventors who share the name “TUCKER HOWARD”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ICI PLC
9 patentsUS4880839ANov 14, 1989
Acyanilide derivatives
ICI PLC171 citations99
US4636505AJan 13, 1987
Amide derivatives
ICI PLC447 citations99
US5189033AFeb 23, 1993
Tricyclic heterocycles
ICI PLC25 citations92
US4873329AOct 10, 1989
Alkene, alkyne or cycloalkylene derivatives
ICI PLC27 citations92
US5317101AMay 31, 1994
Tricyclic heterocycles
ICI PLC19 citations73
US5032592AJul 16, 1991
Alkene, alkyne or cycloalkylene derivatives
ICI PLC15 citations73
US5084478AJan 28, 1992
Alkene, alkyne or cycloalkylene derivatives
ICI PLC5 citations63
US4845119AJul 4, 1989
Alkene, alkyne or cycloalkylene derivatives
ICI PLC5 citations63
US5236953AAug 17, 1993
Alkene, alkyne or cycloalkylene derivatives
ICI PLC1 citations52
ASTRAZENECA AB
8 patentsUS6734184B1May 11, 2004
Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP)
ASTRAZENECA AB20 citations87
US7192973B2Mar 20, 2007
Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
ASTRAZENECA AB15 citations84
US6916817B1Jul 12, 2005
Inhibitors of metalloproteinases
ASTRAZENECA AB8 citations74
US7615555B2Nov 10, 2009
Piperidine derivatives as modulators of chemokine receptor CCR5
ASTRAZENECA AB3 citations61
US7122551B2Oct 17, 2006
Metalloproteinase inhibitor compounds
ASTRAZENECA AB2 citations61
US6734183B2May 11, 2004
Compounds
ASTRAZENECA AB5 citations56
US7342020B2Mar 11, 2008
Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP)
ASTRAZENECA AB0 citations52
US7153857B2Dec 26, 2006
Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
ASTRAZENECA AB0 citations39
ZENECA LTD
6 patentsUS5843942ADec 1, 1998
Aromatic amino ethers as pain relieving agents
ZENECA LTD52 citations92
US5834468ANov 10, 1998
Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
ZENECA LTD32 citations92
US5811459ASep 22, 1998
Ortho substituted aromatic compounds useful as antagonists of the pain enhancing effects of E-type prostaglandins
ZENECA LTD51 citations89
US6057345AMay 2, 2000
Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
ZENECA LTD14 citations73
US5965741AOct 12, 1999
Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief
ZENECA LTD14 citations73
US6787562B2Sep 7, 2004
Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
ZENECA LTD2 citations62
ESD LLC
4 patentsUS5891185AApr 6, 1999
Method and apparatus for treating oropharyngeal disorders with electrical stimulation
ESD LLC140 citations96
US7280873B2Oct 9, 2007
Treatment of oropharyngeal disorders by application of neuromuscular electrical stimulation
ESD LLC61 citations95
US6104958AAug 15, 2000
Device for treating dysphagia with electrical stimulation
ESD LLC71 citations94
US5725564AMar 10, 1998
Method and apparatus for treating dysphagia with electrical stimulation
ESD LLC93 citations94
ICI LTD
3 patentsUS4085136AApr 18, 1978
Optically-active 1-aryloxy-2-propanol intermediates of (s)-absolute configuration
ICI LTD16 citations74
US4275058AJun 23, 1981
β-Adrenergic blocking alkanolamine derivatives
ICI LTD2 citations63
US4182911AJan 8, 1980
Optically-active 1-aryloxy-2-propanol intermediates of (S)-absolute configuration
ICI LTD5 citations63
ESD LTD LIABILITY COMPANY
2 patentsUS6198970B1Mar 6, 2001
Method and apparatus for treating oropharyngeal respiratory and oral motor neuromuscular disorders with electrical stimulation
ESD LTD LIABILITY COMPANY402 citations97
US7039468B2May 2, 2006
Method and apparatus for treating oropharyngeal disorders with electrical stimulation
ESD LTD LIABILITY COMPANY93 citations95